Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMMPatients

Sponsor: Incyte
Protocol Number: I-RUX-15-04
Start Date: 2/6/2017
Active, projected trial end date 6/2021